Posted by Michael Wonder on 11 Mar 2023
Acadia Pharmaceuticals announces US FDA approval of Daybue (trofinetide) for the treatment of Rett syndrome in adult and paediatric patients two years of age and older
10 March 2023 - Company expects Daybue to be available by the end of April 2023.
Acadia Pharmaceuticals today announced that the US FDA has approved Daybue (trofinetide) for the treatment of Rett syndrome in adult and paediatric patients two years of age and older.
